Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 30 May 2025 |
| Transaction in Own Shares | 29 May 2025 |
| Transaction in Own Shares | 28 May 2025 |
| GSK stops Phase 3 trial on cUTIs for efficacy | 28 May 2025 |
| Transaction in Own Shares | 27 May 2025 |
| FDA approves Nucala COPD indication | 23 May 2025 |
| Transaction in Own Shares | 23 May 2025 |
| positive CHMP opinion on Blenrep in EU | 23 May 2025 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 22 May 2025 |
| Transaction in Own Shares | 21 May 2025 |
| Transaction in Own Shares | 20 May 2025 |
| Director/PDMR Shareholding | 20 May 2025 |